Business Wire

CA-QUANERGY-SYSTEMS

Share
Quanergy Secures First AI-Powered 3D LiDAR Integration with Industry Leading Security Center Platform From Genetec

Quanergy Systems, Inc. , a leading provider of LiDAR (Light Detection and Ranging) sensors and smart perception solutions, today announced the first commercial integration of 3D AI-powered LiDAR solutions with the Genetec Inc. (“Genetec”) Security Center unified security platform. The integrated solutions will provide advanced people flow and occupancy management in smart spaces as well as enhanced threat detection and surveillance in high-security environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005262/en/

Quanergy’s high-performance AI-powered 3D LiDAR solution will be integrated to the Genetec unified security platform, allowing its use in multiple specialized Security Center modules including Restricted Security Area, Passenger Flow Analytics, and Occupancy Management package to help automate security, people counting and social distancing applications. Adding Quanergy’s 3D LiDAR and sensor data flow to Genetec Security Center provides increased real-time accuracy for a clearer read on actual footfall traffic, occupancy and proximity in a wide variety of industrial applications from transit systems, airports and industrial facilities to public facing businesses including banking and retail.

“Quanergy’s LiDAR flow management solutions bring a new level of real-time 3D insights that make them ideal for any environment where high accuracy and operational intelligence are critical,” said Enzo Signore, CMO at Quanergy. “Our tight integration with the Genetec Security Center unified platform enables a unique level of automation of many applications across retail, critical infrastructure, airport, seaport, enterprise, and smart cities.”

“We are excited to be integrating Quanergy's 3D LiDAR flow management solutions within Genetec Security Center,” said David Lenot, Airport Product Leader at Genetec. “By bringing their 3D LiDAR sensor data into the traffic and passenger flow modules in our unified platform, we’re helping airports and other organizations address pressing needs while also unlocking new insights into their security operations.”

Quanergy’s AI-powered LiDAR solution accurately and reliably monitor wide areas in real-time in a variety of environments without compromising people’s privacy. The new integrated 3D LiDAR-based solutions will provide:

  • 98%+ detection accuracy: Quanergy QORTEX People Counter accurately detects the number and direction of people, entering in and out of common areas. This can also be used to detect tailgating and increase the security of critical areas. QORTEX People Counter accuracy is significantly higher than camera-based system.
  • Dramatic reduction in false alarms: Quanergy’s QORTEX DTC solution significantly reduces false alarms typical of camera-based systems due to its advanced object detection, tracking, and classification capabilities.
  • 5X - 20X lower TCO (total cost of ownership) than camera-based systems due to very wide coverage (360 degree) and long range (40-70m). A single sensor can cover the area upwards of 8000 m2 . This broad area coverage also reduces installation and cabling costs.
  • Rich 3D, real-time data: Quanergy’s flow management solutions provide accurate centimeter level information about the number of objects, their spatial location, direction, and speed. Quanergy solutions also can detect distance between people to accurately monitor and manage social distancing policies.
  • Privacy protection without compromising or storing private personal information. The LiDAR solutions do not use facial recognition technology nor require opt-in by users; they therefore guarantee the anonymity of people and pose zero PII risk.
  • Reliable & Scalable: Works in all lighting and atmospheric conditions so security systems can effectively operate 24/7.

The integrated solutions are available and can be ordered immediately.

For more information, please visit us at www.quanergy.com/contact .

About Quanergy

Quanergy was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers a high-performance AI-powered LiDAR platform designed to accelerate the automation of key business processes to increase productivity, efficiency, and safety of our 3D world. By providing actionable insights to organizations across major industries including, mapping, security, smart cities and smart spaces, industrial automation and transportation, Quanergy is enabling its partners and their end-users to deploy innovative solutions to drive their business growth and ultimately, improve the quality of life for people around the world. For more information, visit www.quanergy.com .

© Genetec Inc., 2020. Genetec, Security Center and the Genetec logo are trademarks of Genetec Inc. and may be registered or pending registration in several jurisdictions. Other trademarks used in this document may be trademarks of the manufacturers or vendors of the respective product.

Link:

ClickThru

Social Media:

https://www.facebook.com/quanergy

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release

Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye